For the Embr hot flash control gizmo, visit https://myrcc.redcapcloud.com/?#join=… if you signed up and have not heard back from Embr, make sure you signed your Informed Consent. Check your email OR call Embr.
Editor’s Pick:11,201 could be an alltimer’s AnCan record opening PSA – and now it’s undetectible!! (rd)
Topics Discussed
PSA of 11,000+ drops to undetectible!; Keytruda sensitivity test for a BRCA2 guy entering trial; abi or PARP for another BRCA2 man; AnCan stalwarts uses BAT until Lu177 PSMA available; Lu177 PSMA Manaed Care Access trials; lipid panel discussion and new drug that cuts LDL; Embr hot flash gizmo in action; IMRT or SBRT when treating the gland alone for Mx men; side effects during treatment from gland IMRT start to hit; can a man with recurrent PCa consider a drug holiday?; serious rash from Orgovyx is news to Myovant
Chat Log
Jim Ward (to Everyone): 3:04 PM: You’re cat is way too uptight, Jimmie.
Jimmy Greenfield (to Everyone): 3:06 PM: Stressed!
Joe Gallo (to Organizer(s) Only): 3:30 PM: Would a PSMA PET be helpful – more sensitive for mets
Jake (to Everyone): 3:32 PM: peterk@ancan.org
Carlos Huerta (to Everyone): 3:42 PM: It is being done UCLA. Dr Weidhause is collecting the data.
Carlos Huerta (to Everyone): 3:47 PM: I believe it is called MiraDx. Your Onc can call her and have the mouth swab sent out. Joanne Weihaas MD. They are checking for a KRAS-variant. Regarding the Keytruda sensitivity test/study?
Len Sierra (to Everyone): 4:20 PM: Findings of a Phase III imaging study, unveiled at the American Heart Association’s annual conference, show that adding Repatha (evolocumab) to statin therapy resulted in statistically significant regression of atherosclerosis in patients with coronary artery disease (CAD), indicating the drug might offer a key advantage over statin therapy.
Len Sierra (to Everyone): 4:45 PM: Published online 2016 May 6. doi: 10.3389/fonc.2016.00114 PMCID: PMC4858516 PMID: 27200300 Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
Pat Martin (to Everyone): 4:49 PM: See you all next Monday
John Ivory (to Everyone): 4:57 PM: One other way to ask the question–instead of asking if you’re getting sbrt, why not say, “I talked to someone who got sbrt and it only took 5 sessions. Can you tell me why it will take me so many more?”
Len Sierra (to Everyone): 4:58 PM: Good suggestion, John!
Herb Geller (to Organizer(s) Only): 5:07 PM: I gotta go, sorry. I’m in the hot seat next week.
Jake (to Everyone): 5:07 PM: Night,
Herb kang (to Everyone): 5:07 PM: take courage to try
Herb Geller (to Everyone): 5:08 PM: I gotta go. See you next week.
Julian Morales (to Everyone): 5:10 PM: Gotta go too – see you next week. thanks!
Bruce Bocian (to Everyone): 5:11 PM: Ill be seeing Smulewitz this month! I see Vandeerweele tomorrow
Len Sierra (to Everyone): 5:13 PM: Dropping off, guys. See you next week!
Don Price Boulder colorado (to Everyone): 5:16 PM: see all next time…dinner time here.
Jake (to Everyone): 5:23 PM: Thanks Peter!
Gary Peters (to Everyone): 5:24 PM: Dropping off guys. Have a good week
On Aug 4th, Dr. Martin Tenniswood(Chief Scientific Officer – miR Scientific) spoke at our Active Surveillance Virtual Support Group with a special presentation titled “The Future of Liquid Biopsies in Active Surveillance”
Dr. Tenniswood is the co-founder of miR Scientific, which is developing a new liquid biopsy known as Sentinel. He has been searching for the “Holy Grail,” a liquid biopsy for prostate cancer, throughout his 40-year career. He spoke about his search and research in this arena.
We want to thank Dr. Tenniswood for answering questions!
To view the slides from this presentation, click here.
For information on our peer-led video chat ACTIVE SURVEILLANCE PROSTATE CANCER VIRTUAL SUPPORT GROUP, click here.
To SIGN UP for the Group or any other of our AnCan Virtual Support groups, visit our Contact Us page.
On July 29th, we hosted an informational webinar titled “Is Gleason 6 Really Prostate Cancer? – A Debate!“.
Dr. Ming Zhou (Pathologist-in-Chief and Chair of Anatomic and Clinical Pathology, Tufts Medical School), and Dr. Scott Eggener (Vice Chair of Urology at the University of Chicago), each presented their cases at the AnCan program in this video.
Dr. Zhou took the view that if it looks like a cancer, which Gleason does under the microscope, then it’s a cancer. One of Dr. Eggener’s key points, in response, is that he has never seen a patient die from Gleason 6 so why call it a cancer.
The question-and-answer period covered such issues as whether a high-volume Gleason 6 is more risky than a low-volume Gleason 3+4=7. Dr. Eggener argued that these Gleason 6’s can be risky. He also said not enough men with 3+4 go in AS. The doctors engage in an informative and entertaining cross-fire discussion that should not be missed.
So who won? Our poll showed that before the debate: that 55% of respondents thought Gleason 6 is a cancer, while 10% thought it wasn’t a cancer. 35% were unsure.
The numbers changed dramatically after the debate: Only 22% thought Gleason 6 is cancer, 47% said Gleason 6 is not a cancer, and the remaining 31% were unsure. Dr. Eggener clearly won the debate.
The following day, Dr. Zhou got back to us saying:
“Dr. Eggener has won me over. I am now in his camp. I just proposed to work together to educate pathologists on this topic. As you know, I am also the president of Genitourinary Pathology Society (GUPS, an international GU pathology society). I will do my part to change the name.”
Rick’s view on the webinar is simple: “If there’s a real winner from this debate, it’s that AnCan is bringing the sides closer together!”
I happen to agree!
Watch the must see debate here:
Special thanks to Myovant Sciences – Pfizer, Foundation Medicine, and Advanced Accelerator Applications for sponsoring this webinar.
On July 7th, Dr. Niels Olson(Pathologist, researcher, and Chief Medical Officer, Defense Innovation Unit In Mountainview, California) spoke at our Active Surveillance Virtual Support Group with a special presentation titled “Son, I have prostate cancer. What do I do now?”
Dr. Olson shared about his prostate cancer research journey, both professional and personal. Dr. Olson’s father’s diagnosis with prostate cancer set Olson on this path.
Watch him share his research using machine learning, or “artificial intelligence,” to teach computers how to read slides from radical prostatectomies and biopsies. In some circumstances, machines can outperform humans. But Dr. Olson said the machines are not ready to take over. He explains some of the finer points of pathology in this video.
We want to thank Dr. Olson for answering questions!
Watch here:
(Slides to be posted here soon!)
For information on our peer-led video chat ACTIVE SURVEILLANCE PROSTATE CANCER VIRTUAL SUPPORT GROUP, click here.
To SIGN UP for the Group or any other of our AnCan Virtual Support groups, visit our Contact Us page.
On June 29th, we hosted an exceptionally relevant webinar titled “Is Active Surveillance Safe for Black Men?”. Dr. Willie Underwood (Board Certified Urologist, Executive Director of Buffalo Center for Health Equity, and American Medical Association Board of Trustees member) and Anthony Henry (First Vice President of The Walnut Foundation) joined us for this important conversation.
Dr. Brandon Mahal was scheduled to join us, however he is actively volunteering at the Miami collapse area. Thank you Dr. Mahal for helping, and we hope to see you soon!
We want to sincerely thank Dr. Underwood and Anthony for answering questions, and providing their perspectives.
Watch this fascinating presentation here:
Special thanks to Myovant Sciences – Pfizer, Foundation Medicine, and Advanced Accelerator Applications for sponsoring this webinar.
